ethosuximide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1087 77-67-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ethosuximide
  • ethosuxide
  • etosuximid
  • 3-Methyl-3-ethylsuccinimide
An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
  • Molecular weight: 141.17
  • Formula: C7H11NO2
  • CLOGP: 0.40
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.17
  • ALOGS: -0.15
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.25 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 39.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 25 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 118.30 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Nov. 2, 1960 FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple-drug resistance 200.08 45.75 42 1603 5128 63482249
Seizure 164.38 45.75 76 1569 132558 63354819
Aplastic anaemia 104.83 45.75 28 1617 9541 63477836
Drug ineffective 104.40 45.75 130 1515 1044635 62442742
Status epilepticus 100.59 45.75 30 1615 15203 63472174
Petit mal epilepsy 97.28 45.75 22 1623 3772 63483605
Intellectual disability 91.98 45.75 17 1628 1069 63486308
Generalised tonic-clonic seizure 85.33 45.75 31 1614 28985 63458392
Oropharyngeal oedema 81.58 45.75 13 1632 336 63487041
Epilepsy 65.23 45.75 25 1620 27040 63460337
Suicidal behaviour 60.63 45.75 14 1631 2625 63484752
Myoclonic epilepsy 53.14 45.75 11 1634 1243 63486134
Macroglossia 53.10 45.75 10 1635 695 63486682
Aggression 50.56 45.75 20 1625 23478 63463899

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple-drug resistance 122.59 52.82 30 1230 5209 34950462
Petit mal epilepsy 121.75 52.82 27 1233 3051 34952620
Drug ineffective 105.41 52.82 103 1157 456648 34499023
Seizure 89.04 52.82 52 1208 104805 34850866
Myoclonic epilepsy 79.34 52.82 16 1244 1141 34954530
Tonic convulsion 78.74 52.82 16 1244 1185 34954486
Developmental delay 75.70 52.82 18 1242 2757 34952914
Ataxia 58.19 52.82 21 1239 13832 34941839
Status epilepticus 56.29 52.82 20 1240 12594 34943077

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Petit mal epilepsy 276.51 41.65 58 2505 5669 79736156
Multiple-drug resistance 235.68 41.65 55 2508 8753 79733072
Seizure 165.64 41.65 92 2471 188742 79553083
Drug ineffective 131.85 41.65 166 2397 1080747 78661078
Generalised tonic-clonic seizure 130.25 41.65 50 2513 43860 79697965
Status epilepticus 129.22 41.65 43 2520 24998 79716827
Aplastic anaemia 85.41 41.65 29 2534 17876 79723949
Oropharyngeal oedema 75.58 41.65 13 2550 433 79741392
Myoclonic epilepsy 72.63 41.65 16 2547 1954 79739871
Tonic convulsion 70.73 41.65 16 2547 2204 79739621
Epilepsy 65.34 41.65 30 2533 40830 79700995
Intellectual disability 55.81 41.65 12 2551 1308 79740517
Drug resistance 55.24 41.65 27 2536 42186 79699639
Suicidal behaviour 54.73 41.65 14 2549 3233 79738592
Benzodiazepine drug level decreased 52.89 41.65 7 2556 35 79741790
Ataxia 51.67 41.65 22 2541 25017 79716808
Cerebellar atrophy 51.61 41.65 11 2552 1150 79740675
Developmental delay 50.97 41.65 11 2552 1220 79740605
Macroglossia 45.80 41.65 10 2553 1171 79740654
Drug interaction 45.50 41.65 61 2502 415122 79326703
Somnolence 44.31 41.65 46 2517 238935 79502890

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AD01 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Succinimide derivatives
ATC N03AD51 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Succinimide derivatives
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:176497 geroprotectors
CHEBI has role CHEBI:194338 T-type calcium channel blockers
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
FDA EPC N0000175753 Anti-epileptic Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Absence seizure indication 79631006
Suicidal thoughts contraindication 6471006
Mood swings contraindication 18963009
Depressive disorder contraindication 35489007
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Kidney disease contraindication 90708001 DOID:557
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Acute intermittent porphyria contraindication 234422006 DOID:3890
Disease of liver contraindication 235856003 DOID:409
Neutropenic disorder contraindication 303011007 DOID:1227




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.31 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent T-type calcium channel subunit alpha-1G Ion channel BLOCKER WOMBAT-PK CHEMBL

External reference:

IDSource
4018631 VUID
N0000146944 NUI
D00539 KEGG_DRUG
4018631 VANDF
C0015043 UMLSCUI
CHEBI:4887 CHEBI
CHEMBL696 ChEMBL_ID
DB00593 DRUGBANK_ID
D005013 MESH_DESCRIPTOR_UI
3291 PUBCHEM_CID
1077 INN_ID
7182 IUPHAR_LIGAND_ID
5SEH9X1D1D UNII
4135 RXNORM
4199 MMSL
4701 MMSL
d00227 MMSL
001631 NDDF
387244008 SNOMEDCT_US
44790008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-0237 CAPSULE 250 mg ORAL NDA 19 sections
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-0237 CAPSULE 250 mg ORAL NDA 19 sections
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-2418 SOLUTION 250 mg ORAL ANDA 19 sections
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-2418 SOLUTION 250 mg ORAL ANDA 19 sections
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-2418 SOLUTION 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0670 SOLUTION 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0670 SOLUTION 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0670 SOLUTION 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 23155-532 CAPSULE 250 mg ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 42806-708 CAPSULE 250 mg ORAL ANDA 18 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 42806-711 CAPSULE 250 mg ORAL ANDA 18 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 59762-2250 CAPSULE 250 mg ORAL NDA AUTHORIZED GENERIC 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 59762-2350 SOLUTION 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 59762-2350 SOLUTION 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 61748-024 SOLUTION 250 mg ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 61748-025 CAPSULE 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 61748-025 CAPSULE 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8005 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 18 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 64380-878 CAPSULE 250 mg ORAL ANDA 12 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 64380-878 CAPSULE 250 mg ORAL ANDA 12 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 64380-878 CAPSULE 250 mg ORAL ANDA 12 sections
ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 68382-443 CAPSULE 250 1 ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 69387-108 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 69452-152 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1763 CAPSULE 250 mg ORAL ANDA 12 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1763 CAPSULE 250 mg ORAL ANDA 12 sections